Home » Topics » Regulatory » EMA

EMA
RSS

EMA premature in notification of SomaKit TOC opinion

Sep. 23, 2016

EMA grants PRIME scheme access to Bluebird's Lentiglobin and Juno's JCAR-015

Sep. 22, 2016

AstraZeneca withdraws MAA for cediranib

Sep. 22, 2016

EMA validates BMS' application to extend Opdivo indications

Sep. 21, 2016

EMA issues positive opinion on the MAA for SomaKit TOC

Sep. 20, 2016

Pfizer receives positive CHMP opinion for Ibrance in Europe

Sep. 19, 2016

EMA committee grants positive opinion for conditional approval of Ninlaro

Sep. 19, 2016

EMA committee recommends approval of Parsabiv in E.U.

Sep. 19, 2016

EMA committee recommends E.U. approval of Stelara for moderate to severely active Crohn's disease

Sep. 19, 2016

EMA's CHMP recommends approval of Glyxambi for adults with type 2 diabetes

Sep. 19, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...